Analysts See an Over 26% Upside in AtriCure (ATRC)

Group 1 - AtriCure (NASDAQ:ATRC) is recognized as a promising mid-cap healthcare stock priced under $50, with a bullish outlook from J.P. Morgan analyst Lilia-Celine, who raised the price target from $42 to $48, indicating over 17% upside potential for investors [1] - The company successfully completed its first-in-human atrial procedures using the new Pulsed Field Ablation (PFA) technology in combination with its existing Radiofrequency Ablation (RFA) technology, enhancing the efficiency of cardiac surgery ablation procedures [2] - Consensus sentiment remains bullish on AtriCure, with all six analysts covering the stock issuing Buy ratings, and a 1-year median price target of $51.83, suggesting a 26.6% upside [2] Group 2 - AtriCure specializes in innovative medical devices for Atrial Fibrillation (Afib) treatment, offering solutions for surgical ablation of cardiac tissues and management of left atrial appendage (LAA) [3]